Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Coherus Oncology (CHRS) Income from Continuing Operations: 2013-2025

Historic Income from Continuing Operations for Coherus Oncology (CHRS) over the last 12 years, with Sep 2025 value amounting to -$44.5 million.

  • Coherus Oncology's Income from Continuing Operations rose 6.47% to -$44.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $61.0 million, marking a year-over-year increase of 124.40%. This contributed to the annual value of $28.5 million for FY2024, which is 111.98% up from last year.
  • Per Coherus Oncology's latest filing, its Income from Continuing Operations stood at -$44.5 million for Q3 2025, which was up 0.77% from -$44.9 million recorded in Q2 2025.
  • Coherus Oncology's 5-year Income from Continuing Operations high stood at $197.8 million for Q4 2024, and its period low was -$172.9 million during Q1 2021.
  • Moreover, its 3-year median value for Income from Continuing Operations was -$47.4 million (2025), whereas its average is -$31.6 million.
  • As far as peak fluctuations go, Coherus Oncology's Income from Continuing Operations slumped by 586.19% in 2021, and later spiked by 348.34% in 2024.
  • Over the past 5 years, Coherus Oncology's Income from Continuing Operations (Quarterly) stood at -$45.7 million in 2021, then decreased by 28.75% to -$58.9 million in 2022, then plummeted by 35.30% to -$79.7 million in 2023, then spiked by 348.34% to $197.8 million in 2024, then rose by 6.47% to -$44.5 million in 2025.
  • Its last three reported values are -$44.5 million in Q3 2025, -$44.9 million for Q2 2025, and -$47.4 million during Q1 2025.